아웃소싱 임상시험 및 제제 시장 : 지역별 - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Outsourced Clinical Trials & Formulation Market by Geography : Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

US $ 4,995 ￦ 6,879,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,046,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,699,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 세계 아웃소싱 임상시험 및 제제 시장에 대한 심층 분석을 통해 시장 역학, 성장 촉진요인, 과제 및 신흥 동향에 대한 종합적인 인사이트를 제공합니다. 이 보고서는 2024년부터 2031년까지의 시장 상황을 탐색할 수 있는 상세한 데이터와 통계를 제공하며, 이해관계자들에게 귀중한 자료가 될 것입니다.

세계 아웃소싱 임상시험 및 제제 시장 규모는 2024년 160억 달러로 연평균 6.7% 성장하여 2031년 말에는 196억 달러에 달할 것으로 예상됩니다.

조사 범위

• 추정 시장 가치(2024년) : 160억 달러
• 예상 시장 가치(2031년) : 251억 9,000만 달러
• 세계 시장 성장률(2024-2031년 CAGR) : 6.7%

아웃소싱 임상시험 및 제제 시장 - 보고서 범위:

임상시험의 복잡성 증가와 규제 준수 및 품질 보증에 대한 관심이 높아지면서 제약 및 생명공학 기업들은 임상시험 서비스 및 제제 개발을 아웃소싱하는 추세에 있습니다. 아웃소싱을 통해 기업은 전문 지식을 활용하고 비용을 절감하며 의약품 개발 프로세스를 가속화할 수 있습니다. 또한, 정밀의료와 개인맞춤형 치료의 부상으로 개별 환자군에 맞는 치료법 개발이 요구되면서 임상시험 및 제제 개발 아웃소싱에 대한 수요가 증가하고 있습니다.

시장 촉진요인:

임상시험 및 제제 서비스 아웃소싱은 전문 지식의 필요성, 비용 절감, 효율성 향상 등 여러 가지 요인에 의해 추진되고 있습니다. 아웃소싱을 통해 제약 및 생명공학 기업들은 전 세계 임상시험수탁기관(CRO) 및 제제 개발 기업의 세계 네트워크에 접근하여 다양한 기술과 자원을 활용할 수 있게 됩니다. 또한, 아웃소싱을 통해 기업은 전문 서비스 제공업체의 역량을 활용하면서 자사의 핵심 역량에 집중할 수 있습니다. 의약품 개발의 복잡성 증가와 더불어, 타임라인 단축의 필요성은 아웃소싱 임상시험 및 제제 서비스 수요를 더욱 증가시키고 있습니다.

시장 억제요인:

아웃소싱 임상시험 및 제제 서비스에는 많은 장점이 있지만, 여러 가지 문제점과 위험도 존재합니다. 여기에는 데이터 보안, 지적재산권 보호, 규제 준수에 대한 우려가 포함됩니다. 또한, 수많은 CRO와 제제 개발 업체들이 난립하고 있는 아웃소싱 시장의 파편화로 인해 제약 및 생명공학 기업들이 적절한 파트너를 선별하고 선택하는 데 어려움을 겪고 있습니다. 또한, 세계 아웃소싱에 따른 문화적 차이, 커뮤니케이션 장벽, 물류 문제 등이 협업과 프로젝트 수행에 걸림돌이 될 수 있습니다.

시장 기회:

임상시험 및 제제 아웃소싱 서비스는 서비스 제공업체에게 서비스 내용과 지리적 범위를 확장할 수 있는 큰 기회를 제공합니다. 암, 희귀질환, 생물학적 제제 등의 분야에서 전문 지식에 대한 수요가 증가함에 따라 CRO와 제제 개발 기업은 틈새 역량을 구축하고 혁신적인 솔루션을 개발하여 차별화를 꾀할 수 있습니다. 또한 인공지능, 머신러닝, 실제 데이터 분석과 같은 첨단 기술의 도입은 임상시험 업무와 의약품 개발 프로세스의 효율성과 효과성을 높일 수 있는 기회를 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위/분류
• 시장 정의/범위/제한

제3장 주요 시장 동향

• 시장에 영향을 미치는 주요 동향
• 제품 혁신/개발 동향

제4장 핵심성공요인

• 시장 진출 기업이 채용한 주요 전략
• Porters 분석
• PESTLE 분석
• 주요 규제
• 밸류체인 분석

제5장 시장 배경

• 거시경제 요인
• 예측요인 - 관련성과 영향
• 시장 역학

제6장 COVID-19 위기 분석

• 코로나바이러스 유행에 관한 현재의 견해
• 현재 경제 전망과 회복 시나리오
• COVID19와 영향 분석
  • 제품별 매출
  • 최종사용자별 매출
  • 지역별 매출

제7장 세계의 아웃소싱 임상시험 및 제제 시장 수요 분석과 예측(금액 및 규모)

• 과거 시장 분석(금액), 2019-2023년
• 현재 및 향후 시장 예측(금액), 2024-2031년
  • 전년비 성장 동향 분석
  • 절대적인 기회 분석

제8장 세계의 아웃소싱 임상시험 및 제제 시장 분석과 예측, 제품별

• 소개/주요 조사 결과
• 과거 시장 규모(금액) 분석, 2019-2023년
• 현재 및 향후 시장 규모(금액) 분석과 예측, 2024-2031년
  • 경구 투여 제품
    • 고형 제제
    • 액체 제제
    • 반고형 제제
  • 주사제
  • 기타
• 제품별 시장 매력도 분석

제9장 세계의 아웃소싱 임상시험 및 제제 시장 분석과 예측, 용도별

• 소개/주요 조사 결과
• 과거 시장 규모(금액) 분석, 2019-2023년
• 현재 및 향후 시장 규모(금액) 분석과 예측, 2024-2031년
  • API 제조
  • 충전 마감 제품 제조
  • 의약품 개발
  • 포장/라벨
  • 기타
• 용도별 시장 매력도 분석

제10장 세계의 아웃소싱 임상시험 및 제제 시장 분석과 예측, 최종사용자별

• 소개/주요 조사 결과
• 과거 시장 규모(금액) 분석, 2019-2023년
• 현재 및 향후 시장 규모(금액) 분석과 예측, 2024-2031년
  • 대형 제약회사 및 바이오테크놀러지 기업
  • 중소규모 제약·바이오테크놀러지 기업
  • 신흥/가상 제약회사
  • 식이보충제 회사
• 최종사용자별 시장 매력도 분석

제11장 세계의 아웃소싱 임상시험 및 제제 시장 분석과 예측, 지역별

• 소개
• 소개/주요 조사 결과
• 과거 시장 규모(금액) 분석, 2019-2023년
• 현재 시장 규모(금액) 분석과 예측, 2024-2031년
  • 북미
  • 유럽
  • 아시아태평양
  • 세계 기타 지역
• 지역별 시장 매력도 분석

제12장 북미의 아웃소싱 임상시험 및 제제 시장 분석과 예측

제13장 유럽의 아웃소싱 임상시험 및 제제 시장 분석과 예측

제14장 아시아태평양의 아웃소싱 임상시험 및 제제 시장 분석과 예측

제15장 세계 기타 지역의 아웃소싱 임상시험 및 제제 시장 분석과 예측

• 소개
• 과거 시장 규모(금액) 시장 분류별 동향 분석, 2019-2023년
• 시장 규모(금액) 시장 분류별 예측, 2024-2031년
  • 제품별
  • 용도별
  • 최종사용자별
• 시장 매력 분석
• 성장 촉진요인과 억제요인 - 영향 분석

제16장 시장 구조 분석

• 시장 분석과 기업 계층
• 주요 기업의 시장 점유율 분석

제17장 경쟁 분석

• 경쟁 대시보드
• 경쟁 벤치마크
• 경쟁 상세(잠정 리스트)
  • Lonza Group
  • Catalent, Inc.
  • Thermo Fisher Scientific Inc.(Patheon)
  • Piramal Pharma Solutions
  • BioXcellence(Boehringer Ingelheim International GmbH)
  • Siegfried Holding AG
  • Evotec AG
  • Ascendia Pharmaceuticals
  • Experic Services
  • Quotient Sciences
  • Velesco Pharmaceutical Services, Inc.
  • Elements Group(Avomeen)
  • VxP Pharma
  • Adare Pharmaceuticals, Inc.
  • KP Pharmaceutical Technology Inc.
  • Enteris Biopharma, Inc.
  • Aenova Holding GmbH
  • Ardena Holding NV
  • Pharmaceutics International, Inc.
  • Alcami Corporation, Inc.
  • NextPharma Technologies
  • Corden Pharma International GmbH
  • Corerx, Inc.
  • Recipharm AB
  • Pace Analytical Services, LLC
  • Almac Group, Inc.
  • Cambrex Corporation
  • Rottendorf Pharma GmbH
  • Glatt GmbH
  • Hovione
  • Aphena Pharma Solutions
  • HERMES PHARMA GmbH

제18장 사용되는 가정과 두문자어

제19장 조사 방법

ksm

영문 목차

영문목차

Persistence Market Research presents an in-depth analysis of the global Outsourced Clinical Trials & Formulation Market, providing comprehensive insights into market dynamics, growth drivers, challenges, and emerging trends. This report serves as a valuable resource for stakeholders, offering detailed data and statistics to navigate the market landscape from 2024 to 2031.

The global outsourced clinical trials & formulation market is set to record a market value of US$ 16 Bn in 2024, and expand at a CAGR of 6.7% to reach a market valuation of US$ 19.6 Bn by the end of 2031.

Report Scope:

• Estimated Market Value (2024): USD 16 Billion
• Projected Market Value (2031): USD 25.19 Billion
• Global Market Growth Rate (CAGR 2024 to 2031): 6.7%

Outsourced Clinical Trials & Formulation Market - Report Scope:

The increasing complexity of clinical trials, coupled with the growing emphasis on regulatory compliance and quality assurance, has led pharmaceutical and biotechnology companies to outsource clinical trial services and formulation development. Outsourcing enables these companies to access specialized expertise, reduce costs, and accelerate the drug development process. Furthermore, the rise of precision medicine and personalized therapies has increased the demand for outsourced clinical trials & formulation services, as companies seek to tailor treatments to individual patient populations.

Market Growth Drivers:

The outsourcing of clinical trials & formulation services is driven by several factors, including the need for specialized expertise, cost containment, and increased efficiency. Outsourcing allows pharmaceutical and biotechnology companies to access a global network of contract research organizations (CROs) and formulation development firms, enabling them to tap into diverse skill sets and resources. Additionally, outsourcing enables companies to focus on their core competencies while leveraging the capabilities of specialized service providers. The increasing complexity of drug development, coupled with the need for accelerated timelines, further drives the demand for outsourced clinical trials & formulation services.

Market Restraints:

Despite its numerous benefits, outsourcing clinical trials & formulation services also presents challenges and risks. These include concerns regarding data security, intellectual property protection, and regulatory compliance. Additionally, the fragmentation of the outsourcing landscape, with numerous CROs and formulation development firms competing for business, can make it challenging for pharmaceutical and biotechnology companies to identify and select the right partners. Furthermore, cultural differences, communication barriers, and logistical challenges associated with global outsourcing can hinder collaboration and project execution.

Market Opportunities:

The outsourcing of clinical trials & formulation services presents significant opportunities for service providers to expand their offerings and geographic reach. With the increasing demand for specialized expertise in areas such as oncology, rare diseases, and biologics, CROs and formulation development firms can differentiate themselves by building niche capabilities and developing innovative solutions. Moreover, the adoption of advanced technologies such as artificial intelligence, machine learning, and real-world data analytics presents opportunities to enhance the efficiency and effectiveness of clinical trial operations and formulation development processes.

Key Questions Addressed in the Report:

• What is the Expected Value CAGR of the Outsourced Clinical Trials & Formulation Market?
• What are the Key Factors Driving the Growth of the Outsourced Clinical Trials & Formulation Market?
• Who are the Key Players in the Global Outsourced Clinical Trials & Formulation Market?
• Which Region Holds the Largest Market Share in the Outsourced Clinical Trials & Formulation Market?
• What Strategies are Adopted by Leading Companies to Sustain Growth in the Outsourced Clinical Trials & Formulation Market?

Competitive Landscape and Business Strategies:

Prominent players in the outsourced clinical trials & formulation market include IQVIA, PPD, Charles River Laboratories, and Covance. These companies focus on expanding their service offerings, geographic presence, and technological capabilities to maintain their competitive edge. Strategies such as mergers and acquisitions, strategic partnerships, and investments in R&D are commonly employed to drive growth and enhance market position. Additionally, the adoption of quality management systems, risk-based monitoring, and real-time data analytics is becoming increasingly important to meet the evolving needs of pharmaceutical and biotechnology companies.

Key Companies Profiled:

• Thermo Fisher Scientific Inc. (Patheon)
• Piramal Pharma Solutions
• BioXcellence (Boehringer Ingelheim International GmbH)
• Siegfried Holding AG
• Evotec A.G.
• Ascendia Pharmaceuticals
• Experic Services
• Quotient Sciences
• Velesco Pharmaceutical Services, Inc.
• Elements Group (Avomeen)

Outsourced Clinical Trials & Formulation Market Segmentation:

By Product:

• Oral dosage Forms

oSolid dosage Forms

oLiquid Dosage Forms

oSemi-solid Dosage Forms

• Injectable Dosage Forms
• Others

By Application:

• API Manufacturing
• Fill-Finish Product Manufacturing
• Drug Product Development
• Packaging / labeling
• Others

By End User:

• Big Pharmaceutical /Biotech Companies
• Small & Medium Size Pharma/Biotech Companies
• Emerging/virtual Pharma Companies
• Nutraceutical Companies

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation/ Development Trends

4. Key Success factors

• 4.1. Key Strategies Adopted by market players
• 4.2. Porters Analysis
• 4.3. PESTLE Analysis
• 4.4. Key Regulations
• 4.5. Value Chain Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Rising Geriatric Population
  • 5.2.2. Rising incidence of Chronic Diseases
  • 5.2.3. Patent Expiry and Increasing Demand For Generic Drugs
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID19 Crisis Analysis

• 6.1. Current Perspectives on Coronavirus Outbreak
• 6.2. Current Economic Outlook & Recovery Scenario
• 6.3. COVID19 and Impact Analysis
  • 6.3.1. Revenue By Product
  • 6.3.2. Revenue By End User
  • 6.3.3. Revenue By Region

7. Global Outsourced Clinical Trials & Formulation Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast 2024-2031, by Product

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Outsourced Clinical Trials & Formulation Market Analysis 2019-2023 and Forecast 2024-2031, by Product

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis By Product, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2024-2031
  • 8.3.1. Oral Dosage Products
    • 8.3.1.1. Solid dosage Product
    • 8.3.1.2. Liquid Dosage Product
    • 8.3.1.3. Semi-solid Dosage Product
  • 8.3.2. Injectable Dosage Product
  • 8.3.3. Others
• 8.4. Market Attractiveness Analysis By Product

9. Global Outsourced Clinical Trials & Formulation Market Analysis 2019-2023 and Forecast 2024-2031, by Application

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis By Application, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2024-2031
  • 9.3.1. API Manufacturing
  • 9.3.2. Fill Finish Product Manufacturing
  • 9.3.3. Drug Product Development
  • 9.3.4. Packaging / Labelling
  • 9.3.5. Others
• 9.4. Market Attractiveness Analysis By Application

10. Global Outsourced Clinical Trials & Formulation Market Analysis 2019-2023 and Forecast 2024-2031, by End User

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2023
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2031
  • 10.3.1. Big Pharmaceutical and Biotech Companies
  • 10.3.2. Small and Medium Size Pharma/Biotech Companies
  • 10.3.3. Emerging/Virtual Pharma Companies
  • 10.3.4. Nutraceutical Companies
• 10.4. Market Attractiveness Analysis By End User

11. Global Outsourced Clinical Trials & Formulation Market Analysis 2019-2023 and Forecast 2024-2031, by Region

• 11.1. Introduction
• 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2031
  • 11.3.1. North America
  • 11.3.2. Europe
  • 11.3.3. Asia pacific
  • 11.3.4. Rest of the World
• 11.4. Market Attractiveness Analysis By Region

12. North America Outsourced Clinical Trials & Formulation Market Analysis 2019-2023 and Forecast 2024-2031

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
  • 12.3.1. By Country
    • 12.3.1.1. U.S.
    • 12.3.1.2. Canada
  • 12.3.2. By Product
  • 12.3.3. By Application
  • 12.3.4. By End User
• 12.4. Market Attractiveness Analysis
• 12.5. Drivers and Restraints - Impact Analysis

13. Europe Outsourced Clinical Trials & Formulation Market Analysis 2019-2023 and Forecast 2024-2031

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
  • 13.3.1. By Country
    • 13.3.1.1. U.K.
    • 13.3.1.2. Germany
    • 13.3.1.3. France
    • 13.3.1.4. Italy
    • 13.3.1.5. Spain
    • 13.3.1.6. BENELUX
    • 13.3.1.7. Russia
    • 13.3.1.8. BENELUX
    • 13.3.1.9. Rest of Europe
  • 13.3.2. By Product
  • 13.3.3. By Application
  • 13.3.4. By End User
• 13.4. Market Attractiveness Analysis
• 13.5. Drivers and Restraints - Impact Analysis

14. Asia Pacific Outsourced Clinical Trials & Formulation Market Analysis 2019-2023 and Forecast 2024-2031

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
  • 14.3.1. By Country
    • 14.3.1.1. China
    • 14.3.1.2. Japan
    • 14.3.1.3. South Korea
    • 14.3.1.4. India
    • 14.3.1.5. Australia and New Zealand
    • 14.3.1.6. ASEAN
    • 14.3.1.7. Rest of Asia Pacific
  • 14.3.2. By Product
  • 14.3.3. By Application
  • 14.3.4. By End User
• 14.4. Market Attractiveness Analysis
• 14.5. Drivers and Restraints - Impact Analysis

15. Rest of the World Outsourced Clinical Trials & Formulation Market Analysis 2019-2023 and Forecast 2024-2031

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
  • 15.3.1. By Product
  • 15.3.2. By Application
  • 15.3.3. By End User
• 15.4. Market Attractiveness Analysis
• 15.5. Drivers and Restraints - Impact Analysis

16. Market Structure Analysis

• 16.1. Market Analysis y Tier of Companies
• 16.2. Market Share Analysis of Top Players

17. Competition Analysis

• 17.1. Competition Dashboard
• 17.2. Competition Benchmarking
• 17.3. Competition Deep Dive (Tentative List)
  • 17.3.1. Lonza Group
    • 17.3.1.1. Overview
    • 17.3.1.2. Product Portfolio
    • 17.3.1.3. Key Financials
    • 17.3.1.4. SWOT Analysis
    • 17.3.1.5. Sales Footprint
    • 17.3.1.6. Strategy Overview
  • 17.3.2. Catalent, Inc.
    • 17.3.2.1. Overview
    • 17.3.2.2. Product Portfolio
    • 17.3.2.3. Key Financials
    • 17.3.2.4. SWOT Analysis
    • 17.3.2.5. Sales Footprint
    • 17.3.2.6. Strategy Overview
  • 17.3.3. Thermo Fisher Scientific Inc. (Patheon)
    • 17.3.3.1. Overview
    • 17.3.3.2. Product Portfolio
    • 17.3.3.3. Key Financials
    • 17.3.3.4. SWOT Analysis
    • 17.3.3.5. Sales Footprint
    • 17.3.3.6. Strategy Overview
  • 17.3.4. Piramal Pharma Solutions
    • 17.3.4.1. Overview
    • 17.3.4.2. Product Portfolio
    • 17.3.4.3. Key Financials
    • 17.3.4.4. SWOT Analysis
    • 17.3.4.5. Sales Footprint
    • 17.3.4.6. Strategy Overview
  • 17.3.5. BioXcellence (Boehringer Ingelheim International GmbH)
    • 17.3.5.1. Overview
    • 17.3.5.2. Product Portfolio
    • 17.3.5.3. Key Financials
    • 17.3.5.4. SWOT Analysis
    • 17.3.5.5. Sales Footprint
    • 17.3.5.6. Strategy Overview
  • 17.3.6. Siegfried Holding AG
    • 17.3.6.1. Overview
    • 17.3.6.2. Product Portfolio
    • 17.3.6.3. Key Financials
    • 17.3.6.4. SWOT Analysis
    • 17.3.6.5. Sales Footprint
    • 17.3.6.6. Strategy Overview
  • 17.3.7. Evotec A.G.
    • 17.3.7.1. Overview
    • 17.3.7.2. Product Portfolio
    • 17.3.7.3. Key Financials
    • 17.3.7.4. SWOT Analysis
    • 17.3.7.5. Sales Footprint
    • 17.3.7.6. Strategy Overview
  • 17.3.8. Ascendia Pharmaceuticals
    • 17.3.8.1. Overview
    • 17.3.8.2. Product Portfolio
    • 17.3.8.3. Key Financials
    • 17.3.8.4. SWOT Analysis
    • 17.3.8.5. Sales Footprint
    • 17.3.8.6. Strategy Overview
  • 17.3.9. Experic Services
    • 17.3.9.1. Overview
    • 17.3.9.2. Product Portfolio
    • 17.3.9.3. Key Financials
    • 17.3.9.4. SWOT Analysis
    • 17.3.9.5. Sales Footprint
    • 17.3.9.6. Strategy Overview
  • 17.3.10. Quotient Sciences
    • 17.3.10.1. Overview
    • 17.3.10.2. Product Portfolio
    • 17.3.10.3. Key Financials
    • 17.3.10.4. SWOT Analysis
    • 17.3.10.5. Sales Footprint
    • 17.3.10.6. Strategy Overview
  • 17.3.11. Velesco Pharmaceutical Services, Inc.
    • 17.3.11.1. Overview
    • 17.3.11.2. Product Portfolio
    • 17.3.11.3. Key Financials
    • 17.3.11.4. SWOT Analysis
    • 17.3.11.5. Sales Footprint
    • 17.3.11.6. Strategy Overview
  • 17.3.12. Elements Group (Avomeen)
    • 17.3.12.1. Overview
    • 17.3.12.2. Product Portfolio
    • 17.3.12.3. Key Financials
    • 17.3.12.4. SWOT Analysis
    • 17.3.12.5. Sales Footprint
    • 17.3.12.6. Strategy Overview
  • 17.3.13. VxP Pharma
    • 17.3.13.1. Overview
    • 17.3.13.2. Product Portfolio
    • 17.3.13.3. Key Financials
    • 17.3.13.4. SWOT Analysis
    • 17.3.13.5. Sales Footprint
    • 17.3.13.6. Strategy Overview
  • 17.3.14. Adare Pharmaceuticals, Inc.
    • 17.3.14.1. Overview
    • 17.3.14.2. Product Portfolio
    • 17.3.14.3. Key Financials
    • 17.3.14.4. SWOT Analysis
    • 17.3.14.5. Sales Footprint
    • 17.3.14.6. Strategy Overview
  • 17.3.15. KP Pharmaceutical Technology Inc.
    • 17.3.15.1. Overview
    • 17.3.15.2. Product Portfolio
    • 17.3.15.3. Key Financials
    • 17.3.15.4. SWOT Analysis
    • 17.3.15.5. Sales Footprint
    • 17.3.15.6. Strategy Overview
  • 17.3.16. Enteris Biopharma, Inc.
    • 17.3.16.1. Overview
    • 17.3.16.2. Product Portfolio
    • 17.3.16.3. Key Financials
    • 17.3.16.4. SWOT Analysis
    • 17.3.16.5. Sales Footprint
    • 17.3.16.6. Strategy Overview
  • 17.3.17. Aenova Holding GmbH
    • 17.3.17.1. Overview
    • 17.3.17.2. Product Portfolio
    • 17.3.17.3. Key Financials
    • 17.3.17.4. SWOT Analysis
    • 17.3.17.5. Sales Footprint
    • 17.3.17.6. Strategy Overview
  • 17.3.18. Ardena Holding NV
    • 17.3.18.1. Overview
    • 17.3.18.2. Product Portfolio
    • 17.3.18.3. Key Financials
    • 17.3.18.4. SWOT Analysis
    • 17.3.18.5. Sales Footprint
    • 17.3.18.6. Strategy Overview
  • 17.3.19. Pharmaceutics International, Inc.
    • 17.3.19.1. Overview
    • 17.3.19.2. Product Portfolio
    • 17.3.19.3. Key Financials
    • 17.3.19.4. SWOT Analysis
    • 17.3.19.5. Sales Footprint
    • 17.3.19.6. Strategy Overview
  • 17.3.20. Alcami Corporation, Inc.
    • 17.3.20.1. Overview
    • 17.3.20.2. Product Portfolio
    • 17.3.20.3. Key Financials
    • 17.3.20.4. SWOT Analysis
    • 17.3.20.5. Sales Footprint
    • 17.3.20.6. Strategy Overview
  • 17.3.21. NextPharma Technologies
    • 17.3.21.1. Overview
    • 17.3.21.2. Product Portfolio
    • 17.3.21.3. Key Financials
    • 17.3.21.4. SWOT Analysis
    • 17.3.21.5. Sales Footprint
    • 17.3.21.6. Strategy Overview
  • 17.3.22. Corden Pharma International GmbH
    • 17.3.22.1. Overview
    • 17.3.22.2. Product Portfolio
    • 17.3.22.3. Key Financials
    • 17.3.22.4. SWOT Analysis
    • 17.3.22.5. Sales Footprint
    • 17.3.22.6. Strategy Overview
  • 17.3.23. Corerx, Inc.
    • 17.3.23.1. Overview
    • 17.3.23.2. Product Portfolio
    • 17.3.23.3. Key Financials
    • 17.3.23.4. SWOT Analysis
    • 17.3.23.5. Sales Footprint
    • 17.3.23.6. Strategy Overview
  • 17.3.24. Recipharm AB
    • 17.3.24.1. Overview
    • 17.3.24.2. Product Portfolio
    • 17.3.24.3. Key Financials
    • 17.3.24.4. SWOT Analysis
    • 17.3.24.5. Sales Footprint
    • 17.3.24.6. Strategy Overview
  • 17.3.25. Pace Analytical Services, LLC
    • 17.3.25.1. Overview
    • 17.3.25.2. Product Portfolio
    • 17.3.25.3. Key Financials
    • 17.3.25.4. SWOT Analysis
    • 17.3.25.5. Sales Footprint
    • 17.3.25.6. Strategy Overview
  • 17.3.26. Almac Group, Inc.
    • 17.3.26.1. Overview
    • 17.3.26.2. Product Portfolio
    • 17.3.26.3. Key Financials
    • 17.3.26.4. SWOT Analysis
    • 17.3.26.5. Sales Footprint
    • 17.3.26.6. Strategy Overview
  • 17.3.27. Cambrex Corporation
    • 17.3.27.1. Overview
    • 17.3.27.2. Product Portfolio
    • 17.3.27.3. Key Financials
    • 17.3.27.4. SWOT Analysis
    • 17.3.27.5. Sales Footprint
    • 17.3.27.6. Strategy Overview
  • 17.3.28. Rottendorf Pharma GmbH
    • 17.3.28.1. Overview
    • 17.3.28.2. Product Portfolio
    • 17.3.28.3. Key Financials
    • 17.3.28.4. SWOT Analysis
    • 17.3.28.5. Sales Footprint
    • 17.3.28.6. Strategy Overview
  • 17.3.29. Glatt GmbH
    • 17.3.29.1. Overview
    • 17.3.29.2. Product Portfolio
    • 17.3.29.3. Key Financials
    • 17.3.29.4. SWOT Analysis
    • 17.3.29.5. Sales Footprint
    • 17.3.29.6. Strategy Overview
  • 17.3.30. Hovione
    • 17.3.30.1. Overview
    • 17.3.30.2. Product Portfolio
    • 17.3.30.3. Key Financials
    • 17.3.30.4. SWOT Analysis
    • 17.3.30.5. Sales Footprint
    • 17.3.30.6. Strategy Overview
  • 17.3.31. Aphena Pharma Solutions
    • 17.3.31.1. Overview
    • 17.3.31.2. Product Portfolio
    • 17.3.31.3. Key Financials
    • 17.3.31.4. SWOT Analysis
    • 17.3.31.5. Sales Footprint
    • 17.3.31.6. Strategy Overview
  • 17.3.32. HERMES PHARMA GmbH
    • 17.3.32.1. Overview
    • 17.3.32.2. Product Portfolio
    • 17.3.32.3. Key Financials
    • 17.3.32.4. SWOT Analysis
    • 17.3.32.5. Sales Footprint
    • 17.3.32.6. Strategy Overview

18. Assumptions and Acronyms Used

19. Research Methodology

관련자료